W Marston Linehan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1429121/publications.pdf

Version: 2024-02-01

323 papers	40,210 citations	2544 96 h-index	2684 193 g-index
332 all docs	332 docs citations	332 times ranked	28199 citing authors

#	Article	IF	Citations
1	Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene. Science, 1993, 260, 1317-1320.	12.6	2,723
2	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	21.4	1,461
3	von Hippel-Lindau disease. Lancet, The, 2003, 361, 2059-2067.	13.7	1,322
4	Comparison of MR/Ultrasound Fusionâ€“Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	7.4	1,267
5	Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature, 2012, 481, 385-388.	27.8	1,074
6	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	27.0	1,040
7	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	7.4	994
8	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell, 2005, 8, 143-153.	16.8	843
9	Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-DubÃ© syndrome. Cancer Cell, 2002, 2, 157-164.	16.8	833
10	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	16.8	665
11	The genetic basis of kidney cancer: a metabolic disease. Nature Reviews Urology, 2010, 7, 277-285.	3.8	634
12	Mutations in the Fumarate Hydratase Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North America. American Journal of Human Genetics, 2003, 73, 95-106.	6.2	563
13	Renal Tumors in the Birt-Hogg-DubÃ© Syndrome. American Journal of Surgical Pathology, 2002, 26, 1542-1552.	3.7	544
14	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Human Mutation, 1995, 5, 66-75.	2.5	526
15	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
16	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	3.9	512
17	Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. Clinical Cancer Research, 2008, 14, 4726-4734.	7.0	503
18	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487

#	Article	IF	Citations
19	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	2.5	452
20	The Genetic Basis of Cancer of the Kidney. Journal of Urology, 2003, 170, 2163-2172.	0.4	447
21	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	2.5	436
22	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	28.9	430
23	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557.	7.1	427
24	The contribution of VHL substrate binding and HIF1-Î± to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 2002, 1, 247-255.	16.8	421
25	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. Journal of Clinical Oncology, 2013, 31, 181-186.	1.6	401
26	Germline BHD-Mutation Spectrum and Phenotype Analysis of a Large Cohort of Families with Birt-Hogg-DubÃ© Syndrome. American Journal of Human Genetics, 2005, 76, 1023-1033.	6.2	363
27	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nature Reviews Urology, 2019, 16, 539-552.	3.8	357
28	Birt-Hogg-DubÃ© Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. American Journal of Human Genetics, 2001, 69, 876-882.	6.2	355
29	Lung Cysts, Spontaneous Pneumothorax, and Genetic Associations in 89 Families with Birt-Hogg-DubÃ© Syndrome. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1044-1053.	5.6	318
30	High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4505-4509.	3.6	299
31	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	5.9	298
32	Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 1998, 20, 66-69.	21.4	291
33	Hereditary Papillary Renal Cell Carcinoma. Journal of Urology, 1994, 151, 561-566.	0.4	289
34	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	3.2	282
35	Oxidation of Alpha-Ketoglutarate Is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects. Cell Reports, 2014, 7, 1679-1690.	6.4	281
36	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	3.6	262

#	Article	IF	Citations
37	EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÃ‰ SYNDROME. Journal of Urology, 2005, 173, 1482-1486.	0.4	260
38	Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Familial Cancer, 2014, 13, 637-644.	1.9	251
39	Proteomic analysis of laser capture microdissected human prostate cancer andin vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	2.4	246
40	Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. American Journal of Pathology, 1998, 153, 223-231.	3.8	243
41	Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. American Journal of Pathology, 1999, 155, 517-526.	3.8	243
42	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. Journal of Urology, 2007, 177, 2074-2080.	0.4	235
43	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.4	233
44	Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). Surgery, 2007, 142, 814-818.e2.	1.9	232
45	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.4	229
46	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157.	0.4	227
47	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	3.8	227
48	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154.	6.3	223
49	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-DubÃ©â€“Associated Renal Tumors. Journal of the National Cancer Institute, 2005, 97, 931-935.	6.3	213
50	Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1Î± Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. Molecular and Cellular Biology, 2009, 29, 4080-4090.	2.3	212
51	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.4	211
52	Hereditary Renal Cancers. Radiology, 2003, 226, 33-46.	7.3	210
53	Robotic Partial Nephrectomy for Complex Renal Tumors: Surgical Technique. European Urology, 2008, 53, 514-523.	1.9	210
54	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727.	7.1	203

#	Article	IF	Citations
55	Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Research, 2012, 22, 2089-2100.	5.5	202
56	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 777-781.	0.4	198
57	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell, 2011, 20, 315-327.	16.8	190
58	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.4	188
59	Genetic Basis of Cancer of the Kidney. Clinical Cancer Research, 2004, 10, 6282S-6289S.	7.0	187
60	THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE. Journal of Urology, 2004, 172, 63-65.	0.4	181
61	Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies. Oncologist, 2012, 17, 46-54.	3.7	177
62	Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-DubÃ© syndrome. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 393-400.	2.5	177
63	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. Journal of Urology, 1995, 153, 907-912.	0.4	176
64	Molecular genetics and clinical features of Birtâ€“Hoggâ€“DubÃ© syndrome. Nature Reviews Urology, 2015, 12, 558-569.	3.8	175
65	Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancerâ€”Targeting the Warburg Effect in Cancer. Clinical Cancer Research, 2013, 19, 3345-3352.	7.0	172
66	Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. Journal of Urology, 1995, 154, 2010-2015.	0.4	170
67	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	3.1	169
68	Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors. PLoS Genetics, 2011, 7, e1002312.	3.5	168
69	Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene, 2008, 415, 60-67.	2.2	163
70	The Metabolic Basis of Kidney Cancer. Cancer Discovery, 2019, 9, 1006-1021.	9.4	163
71	LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 68-72.	0.4	159
72	Molecular Diagnosis and Therapy of Kidney Cancer. Annual Review of Medicine, 2010, 61, 329-343.	12.2	154

#	Article	IF	Citations
73	Robotic Partial Nephrectomy for Renal Hilar Tumors: A Multi-Institutional Analysis. Journal of Urology, 2008, 180, 2353-2356.	0.4	147
74	Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. PLoS ONE, 2010, 5, e15793.	2.5	146
75	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Development Research, 2000, 49, 34-42.	2.9	144
76	Characterization of the Renal Pathology of a Familial Form of Renal Cell Carcinoma Associated With Von Hippel-Lindau Disease: Clinical and Molecular Genetic Implications. Journal of Urology, 1995, 153, 22-26.	0.4	143
77	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	3.4	135
78	Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management. Journal of Clinical Oncology, 2014, 32, 431-437.	1.6	135
79	FLCN : The causative gene for Birt-Hogg-DubÃ© syndrome. Gene, 2018, 640, 28-42.	2.2	133
80	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. Journal of Urology, 1993, 150, 463-466.	0.4	132
81	The metabolic basis of kidney cancer. Seminars in Cancer Biology, 2013, 23, 46-55.	9.6	132
82	Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics. Clinical Cancer Research, 2007, 13, 671s-679s.	7.0	131
83	UOK 262 cell line, fumarate hydratase deficient (FHâ^'/FHâ^') hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55.	1.0	131
84	FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. Journal of Urology, 1998, 160, 335-340.	0.4	127
85	Expression of Birtâ€"Hoggâ€"DubÃ© gene mRNA in normal and neoplastic human tissues. Modern Pathology, 2004, 17, 998-1011.	5.5	124
86	CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1997, 158, 1675-1678.	0.4	120
87	Focus on kidney cancer. Cancer Cell, 2004, 6, 223-228.	16.8	119
88	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. Journal of Urology, 2004, 172, 1256-1261.	0.4	115
89	Hereditary leiomyomatosis and renal cell carcinoma. International Journal of Nephrology and Renovascular Disease, 2014, 7, 253.	1.8	112
90	Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma. American Journal of Surgical Pathology, 2010, 34, 757-766.	3.7	111

#	Article	IF	Citations
91	Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene, 1999, 18, 1205-1208.	5.9	108
92	Genetic predisposition to kidney cancer. Seminars in Oncology, 2016, 43, 566-574.	2.2	107
93	INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. Journal of Urology, 1999, 162, 43-45.	0.4	102
94	Surgical Management of Pheochromocytoma with the Use of Metyrosine. Annals of Surgery, 1990, 212, 621-628.	4.2	101
95	Hereditary kidney cancer. Cancer, 2009, 115, 2252-2261.	4.1	101
96	Translocation Renal Cell Carcinomas in Adults. American Journal of Surgical Pathology, 2012, 36, 654-662.	3.7	98
97	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. Journal of Urology, 1999, 161, 395-398.	0.4	97
98	Epididymal cystadenomas in von Hippel-Lindau disease. Urology, 1997, 49, 926-931.	1.0	96
99	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. Journal of the National Cancer Institute, 2016, 108, djv287.	6.3	92
100	PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. Journal of Urology, 2000, 163, 431-433.	0.4	91
101	Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. Hepatology, 2015, 62, 1122-1131.	7.3	91
102	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. Journal of Urology, 1990, 144, 614-617.	0.4	90
103	Partial adrenalectomy: The National Cancer Institute experience. Urology, 2005, 66, 19-23.	1.0	89
104	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17.	7.0	88
105	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. Journal of Urology, 1995, 153, 913-916.	0.4	87
106	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	16.8	87
107	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cancer Research, 2016, 76, 2177-2185.	0.9	86
108	Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Human Mutation, 2004, 23, 40-46.	2.5	85

#	Article	IF	Citations
109	Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer. Journal of Urology, 2013, 190, 1990-1998.	0.4	85
110	Diagnosis and management of BHD-associated kidney cancer. Familial Cancer, 2013, 12, 397-402.	1.9	85
111	Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. Cell Reports, 2014, 7, 412-423.	6.4	84
112	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84
113	Endolymphatic sac tumors in von Hippelâ€"Lindau disease. Journal of Neurosurgery, 2004, 100, 480-487.	1.6	83
114	Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. Journal of Urology, 2008, 179, 67-70.	0.4	83
115	Association of Germline Mutations in the Fumarate Hydratase Gene and Uterine Fibroids in Women With Hereditary Leiomyomatosis and Renal Cell Cancer. Archives of Dermatology, 2008, 144, 1584-92.	1.4	83
116	Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. Journal of the National Cancer Institute, 2012, 104, 1750-1764.	6.3	82
117	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-Î² signaling. Molecular Cancer, 2010, 9, 160.	19.2	81
118	Development of a prostate cDNA microarray and statistical gene expression analysis package. , 2000, 28, 12-22.		80
119	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology, 2019, 76, 754-764.	1.9	80
120	Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. PLoS ONE, 2013, 8, e72179.	2.5	80
121	EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEOBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. Journal of Urology, 2001, 165, 1329-1334.	0.4	79
122	Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. Cell Chemical Biology, 2017, 24, 231-242.	5.2	79
123	ONC201 kills breast cancer cellsin vitroby targeting mitochondria. Oncotarget, 2018, 9, 18454-18479.	1.8	77
124	A chemoproteomic portrait of the oncometabolite fumarate. Nature Chemical Biology, 2019, 15, 391-400.	8.0	77
125	Englerin A Stimulates PKCÎ¸ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality. Cancer Cell, 2013, 23, 228-237.	16.8	74
126	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1624-31.	7.1	74

#	Article	IF	Citations
127	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid InÂVivo Metabolic Rewiring and Vulnerability to Combination Therapy. Cell Reports, 2020, 30, 1798-1810.e4.	6.4	73
128	Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. Science, 2021, 373, 236-241.	12.6	71
129	Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomatosis. JAMA Ophthalmology, 2007, 125, 239.	2.4	70
130	Acute loss of ironâ€“sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. Journal of Biological Chemistry, 2018, 293, 8297-8311.	3.4	70
131	Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2011, 2, 515-526.	2.5	69
132	Studying Cancer Families to Identify Kidney Cancer Genes. Annual Review of Medicine, 2003, 54, 217-233.	12.2	66
133	Targeting the Met signaling pathway in renal cancer. Expert Review of Anticancer Therapy, 2009, 9, 785-793.	2.4	66
134	Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. Journal of Urology, 2009, 182, 1280-1286.	0.4	66
135	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. Journal of Urology, 2010, 184, 1855-1859.	0.4	66
136	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797.	6.4	64
137	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydrataseâ€“deficient renal cancer. Science Signaling, 2021, 14, .	3.6	64
138	Imaging Features of Hereditary Papillary Renal Cancers. Journal of Computer Assisted Tomography, 1997, 21, 737-741.	0.9	63
139	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. European Urology, 2013, 63, 244-251.	1.9	61
140	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	1.9	60
141	Robot-Assisted Laparoscopic Partial Adrenalectomy for Pheochromocytoma: The National Cancer Institute Technique. European Urology, 2011, 60, 118-124.	1.9	58
142	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5977-5989.	7.0	58
143	Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. PLoS ONE, 2014, 9, e85621.	2.5	58
144	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-DubÃ© syndrome is required for murine B-cell development. Blood, 2012, 120, 1254-1261.	1.4	57

#	Article	IF	Citations
145	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nature Communications, 2016, 7, 12037.	12.8	56
146	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). PLoS ONE, 2015, 10, e0140257.	2.5	56
147	The UOK 257 cell line: a novel model for studies of the human Birtâ€“Haggâ€“DubÃ© gene pathway. Cancer Genetics and Cytogenetics, 2008, 180, 100-109.	1.0	55
148	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390.	0.4	55
149	MicroRNAâ€204â€5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Science, 2019, 110, 1897-1908.	3.9	55
150	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Human Molecular Genetics, 2014, 23, 5706-5719.	2.9	54
151	Differential expression of the mismatch repair genehMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer, 2002, 94, 690-699.	4.1	53
152	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. Journal of Clinical Oncology, 2020, 38, 5004-5004.	1.6	53
153	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opinion on Biological Therapy, 2008, 8, 779-790.	3.1	51
154	Identification of intragenic deletions and duplication in the FLCN gene in Birtâ€Haggâ€DubÃ© syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477.	2.8	50
155	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. International Journal of Biochemistry and Cell Biology, 2009, 41, 753-756.	2.8	49
156	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156.	2.8	48
157	Management of von Hippelâ€“Lindau-associated kidney cancer. Nature Reviews Urology, 2005, 2, 248-255.	1.4	48
158	Robot-assisted Laparoscopic Partial Adrenalectomy: Initial Experience. Urology, 2011, 77, 775-780.	1.0	47
159	Evaluation of Color Doppler Intraoperative Ultrasound in Parenchymal Sparing Renal Surgery. Journal of Urology, 1994, 152, 1984-1987.	0.4	44
160	Intratumoral heterogeneity in kidney cancer. Nature Genetics, 2014, 46, 214-215.	21.4	44
161	Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippelâ€“Lindau Disease. JAMA Oncology, 2018, 4, 124.	7.1	44
162	The genetic basis of cancer of kidney cancer: implications for geneâ€specific clinical management. BJU International, 2005, 95, 2-7.	2.5	43

#	Article	IF	Citations
163	Clinical features, genetics and potential therapeutic approaches for Birtâ€“Hoggâ€“DubÃ© syndrome. Expert Opinion on Orphan Drugs, 2015, 3, 15-29.	0.8	43
164	Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. Journal of Clinical Oncology, 2018, 36, 3540-3546.	1.6	41
165	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	1.0	40
166	Phase II study of the oral HIF-2Î± inhibitor MK-6482 for Von Hippel-Lindau diseaseâ€“associated renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5003-5003.	1.6	40
167	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	1.6	39
168	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. Cell Reports, 2019, 26, 1344-1356.e5.	6.4	38
169	Improved detection of germline mutations in the von Hippelâ€Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	2.5	38
170	Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. Journal of Neurosurgery, 2016, 124, 971-976.	1.6	37
171	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Cell, 2018, 173, 540-542.	28.9	37
172	Non-Clear Cell Renal Cancer: Disease-Based Management and Opportunities for Targeted Therapeutic Approaches. Seminars in Oncology, 2013, 40, 511-520.	2.2	36
173	Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 42-49.	7.0	36
174	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	1.9	36
175	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	16.8	35
176	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118.	2.1	35
177	Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733.	1.8	35
178	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. Molecular Cancer Research, 2019, 17, 1613-1626.	3.4	35
179	Germline mutations in the Von Hippelâ€Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	2.5	33
180	Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes and Cancer, 1994, 11, 15-20.	2.8	32

#	Article	IF	Citations
181	Targeted therapies for non-clear renal cell carcinoma. Targeted Oncology, 2010, 5, 119-129.	3.6	32
182	A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. Journal of Urology, 1991, 145, 1040-1042.	0.4	31
183	Kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 948-951.	1.6	31
184	Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 23.e9-23.e13.	1.6	30
185	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine, 2010, 8, 8.	4.4	29
186	Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. American Journal of Human Genetics, 2018, 103, 358-366.	6.2	29
187	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood, 2021, 137, 126-137.	1.4	29
188	Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. JAMA Dermatology, 2015, 151, 770.	4.1	28
189	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069.	4.1	28
190	Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression. Journal of Biomolecular Screening, 2006, 11, 678-687.	2.6	25
191	Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle, 2010, 9, 4183-4189.	2.6	25
192	Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells, 2016, 34, 1068-1082.	3.2	25
193	Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. Journal of Endourology, 2016, 30, 1219-1226.	2.1	25
194	Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. Journal of the American Chemical Society, 2016, 138, 15813-15816.	13.7	25
195	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. Clinical Imaging, 2021, 77, 291-298.	1.5	25
196	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. Journal of Urology, 2003, 169, 274-275.	0.4	24
197	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. Cancer, 2009, 115, 2247-2251.	4.1	24
198	Discoveries, therapies and opportunities. Nature Reviews Urology, 2014, 11, 614-616.	3.8	24

#	Article	IF	Citations
199	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e13-167.e20.	1.6	24
200	Patient-specific factors influence somatic variation patterns in von Hippelâ€“Lindau disease renal tumours. Nature Communications, 2016, 7, 11588.	12.8	24
201	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186.	5.4	24
202	Therapeutic inhibition of HIF-2Î± reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood, 2021, 137, 2509-2519.	1.4	24
203	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301.	1.0	23
204	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2Î± induced gene expression. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2113-2115.	2.2	23
205	The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. European Urology, 2012, 61, 896-898.	1.9	23
206	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birtâ€“Hoggâ€“DubÃ© tumors. Modern Pathology, 2015, 28, 1458-1469.	5.5	23
207	Targeting HIF2Î± in Clear-Cell Renal Cell Carcinoma. Cancer Cell, 2016, 30, 515-517.	16.8	23
208	Multiple painful cutaneous nodules and renal mass. Journal of the American Academy of Dermatology, 2006, 55, 683-686.	1.2	22
209	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. Academic Radiology, 2021, 28, 1491-1499.	2.5	22
210	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology, 2021, 149, 89-97.	1.0	22
211	The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. Prostate, 1987, 10, 189-197.	2.3	21
212	Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. Cancer, 1997, 81, 180-186.	4.1	21
213	Familial Renal Cancer: Molecular Genetics and Surgical Management. International Journal of Surgical Oncology, 2011, 2011, 1-11.	0.6	21
214	Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	2.8	21
215	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2003, 169, 357-360.	0.4	20
216	Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. Current Urology Reports, 2011, 12, 47-55.	2.2	20

#	Article	IF	Citations
217	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology, 2019, 124, 91-97.	1.0	20
218	Targeting HIF2Î± Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma. Oncotarget, 2012, 3, 1472-1482.	1.8	20
219	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. Nature Structural and Molecular Biology, 2021, 28, 662-670.	8.2	19
220	Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. ELife, 2019, 8, .	6.0	19
221	A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer, 1992, 69, 213-218.	4.1	18
222	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. Diagnostic Cytopathology, 2001, 24, 328-332.	1.0	18
223	PARENCHYMAL SPARING SURGERY FOR CENTRAL RENAL TUMORS IN PATIENTS WITH HEREDITARY RENAL CANCERS. Journal of Urology, 2004, 172, 49-53.	0.4	18
224	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. International Urology and Nephrology, 2016, 48, 1817-1821.	1.4	18
225	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. Cell Reports, 2020, 30, 1823-1834.e5.	6.4	18
226	Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management. Journal of Clinical Oncology, 2009, 27, 3731-3733.	1.6	17
227	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392.	2.9	17
228	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nature Communications, 2020, 11, 6314.	12.8	17
229	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 3596-3603.	2.5	17
230	Hypoxia-Inducible Factor 2Î± Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	5.3	16
231	Photoinducible Oncometabolite Detection. ChemBioChem, 2019, 20, 360-365.	2.6	16
232	Inhibition of Hypoxia Inducible Factor-2 Transcription: Isolation of Active Modulators from Marine Sponges. Journal of Natural Products, 2012, 75, 1632-1636.	3.0	15
233	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas. JAMA Dermatology, 2015, 151, 1096.	4.1	15
234	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. Urology, 2020, 140, 85-90.	1.0	15

#	Article	IF	Citations
235	Tonantzitlolone cytotoxicity toward renal cancer cells is PKCÎ¸- and HSF1-dependent. Oncotarget, 2015, 6, 29963-29974.	1.8	15
236	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1998, 159, 1148-1151.	0.4	14
237	Targeting VEGF receptors in kidney cancer. Lancet Oncology, The, 2007, 8, 956-957.	10.7	14
238	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindauâ€“Associated Pancreatic Lesions. Journal of the American College of Surgeons, 2014, 218, 997-1003.	0.5	14
239	RCC â€” advances in targeted therapeutics and genomics. Nature Reviews Urology, 2017, 14, 76-78.	3.8	14
240	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729.	2.8	14
241	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724.	2.9	14
242	Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	8.2	14
243	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenaseâ€“Deficient Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 6302-6308.	7.0	13
244	Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. , 1999, 87, 231-237.		12
245	Partial adrenalectomy in patients with multiple adrenal tumors. Current Urology Reports, 2001, 2, 19-23.	2.2	12
246	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippelâ€“Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1631-1638.	3.6	12
247	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research, 2018, 78, 6539-6548.	0.9	12
248	Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. Methods in Molecular Biology, 2019, 1928, 1-27.	0.9	12
249	Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. Genes, 2021, 12, 261.	2.4	12
250	PULMONARY INFARCTS CAN MIMIC PULMONARY METASTASES FROM RENAL CANCER. Journal of Urology, 1997, 158, 1688-1690.	0.4	11
251	Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 134.e1-134.e8.	1.6	11
252	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	4.1	11

#	Article	IF	Citations
253	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget, 2017, 8, 17628-17642.	1.8	11
254	Molecular Genetics of Tumor Suppressor Genes in Prostate Carcinoma: the Challenge and the Promise Ahead. Journal of Urology, 1992, 147, 808-809.	0.4	10
255	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World Journal of Urology, 1996, 14, S2-7.	2.2	10
256	Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. Scientific Reports, 2019, 9, 18409.	3.3	10
257	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. Clinical Imaging, 2020, 68, 14-19.	1.5	10
258	Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippelâ€“Lindau Disease. Radiology, 2020, 295, 583-590.	7.3	10
259	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes Chromosomes and Cancer, 2021, 60, 434-446.	2.8	10
260	Reoperative Partial Nephrectomyâ€”Does Previous Surgical Footprint Impact Outcomes?. Journal of Urology, 2021, 206, 539-547.	0.4	10
261	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. JCO Precision Oncology, 2017, 1, 1-14.	3.0	9
262	Birt-Hogg-DubÃ© syndrome initially diagnosed as tuberous sclerosis complex. JAAD Case Reports, 2019, 5, 368-371.	0.8	9
263	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. Genes and Development, 2019, 33, 1641-1656.	5.9	9
264	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. Journal of Urology, 2001, 165, 1623-1624.	0.4	8
265	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e15-27.e21.	1.6	8
266	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. Pharmaceutical Research, 2016, 33, 2459-2469.	3.5	8
267	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1221-1223.	9.4	8
268	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. Journal of Medical Genetics, 2020, , jmedgenet-2020-107308.	3.2	8
269	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. Cell Reports Methods, 2022, 2, 100136.	2.9	8
270	Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. International Urology and Nephrology, 2016, 48, 1047-1053.	1.4	7

#	Article	IF	Citations
271	Vascular Endothelial Growth Factor Receptorâ€“Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. Journal of Clinical Oncology, 2016, 34, e76-e79.	1.6	7
272	Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. International Journal of Radiation Oncology Biology Physics, 2018, 100, 344-352.	0.8	7
273	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindauâ€“associated Solid Pancreatic Tumors. Radiology, 2019, 290, 116-124.	7.3	7
274	Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. Journal of Biological Chemistry, 2020, 295, 13410-13418.	3.4	7
275	Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes and Cancer, 2020, 59, 472-483.	2.8	7
276	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	2.4	7
277	The origin, evolution and route to metastasis of clear cell RCC. Nature Reviews Nephrology, 2018, 14, 538-540.	9.6	6
278	Comprehensive characterization of Alu â€mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Human Mutation, 2021, 42, 520-529.	2.5	6
279	X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. Urology, 2021, 154, 315-319.	1.0	6
280	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. Urology Case Reports, 2019, 27, 100922.	0.3	5
281	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. Biochemical and Biophysical Research Communications, 2020, 522, 931-938.	2.1	5
282	Intravitreous treatment of severe ocular von <scp>Hippelâ€“Lindau</scp> disease using a combination of the <scp>VEGF</scp> inhibitor, ranibizumab and <scp>PDGF</scp> inhibitor, <scp>E10030</scp>: Results from a phase 1/2 clinical trial. Clinical and Experimental Ophthalmology, 2021, 49, 1048-1059.	2.6	5
283	Renal Cell Carcinoma. Journal of Urology, 1988, 139, 340-341.	0.4	4
284	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. Journal of Surgical Oncology, 1993, 53, 252-255.	1.7	4
285	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. Breast Journal, 1998, 4, 9-12.	1.0	4
286	Kidney cancer: Opportunity for disease specific targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 542.	1.6	4
287	Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. Journal of Cancer, 2011, 2, 271-279.	2.5	4
288	Treating advanced kidney cancerâ€”miles to go before we sleep. Nature Reviews Clinical Oncology, 2013, 10, 614-615.	27.6	4

#	Article	IF	Citations
289	Looking forward, looking backâ€”10 years in urology. Nature Reviews Urology, 2014, 11, 649-655.	3.8	4
290	Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 220-225.	3.8	4
291	The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. Nature Reviews Urology, 2018, 15, 731-732.	3.8	4
292	An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. ACS Chemical Biology, 2020, 15, 856-861.	3.4	4
293	18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. Abdominal Radiology, 2021, 46, 3301-3308.	2.1	4
294	Treatment of Advanced Renal Cell Carcinoma. , 2012, , 1475-1491.e5.		4
295	Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181.	1.8	4
296	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. IScience, 2022, 25, 104463.	4.1	4
297	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	4
298	A mouse model of renal cell carcinoma. Nature Medicine, 2017, 23, 802-803.	30.7	3
299	Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2Î± Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. European Urology, 2019, 75, 882-884.	1.9	3
300	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4584-4584.	1.6	3
301	Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 383-383.	1.6	3
302	Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamideâ€“chlorambucil conjugate. Cancer Science, 2022, 113, 2352-2367.	3.9	3
303	Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. Cancer & Metabolism, 2020, 8, 7.	5.0	2
304	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2021, 12, 5375-5384.	2.5	2
305	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip This article is a US Government work, and, as such, is in the public domain in the United States of America.Questions concerning the Ciphergen SELDI instrumentation should be directed to Tai-Tung Yip, Ciphergen Biosystems, Inc., Palo Alto, CA.. Drug Development Research, 2000, 49, 34.	2.9	2
306	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235.		2

#	Article	IF	Citations
307	Defining early-onset kidney cancer: Implications for genetic counseling.. Journal of Clinical Oncology, 2013, 31, 342-342.	1.6	2
308	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	1.0	2
309	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643.	3.7	2
310	Editorial Comment. Urology, 2014, 83, 675.e5.	1.0	1
311	The Metabolic Basis of Kidney Cancer. , 2015, , 89-102.		1
312	Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. Urology Case Reports, 2017, 13, 101-103.	0.3	1
313	Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. Urology Case Reports, 2017, 13, 107-109.	0.3	1
314	Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. Clinical Genitourinary Cancer, 2019, 17, e482-e484.	1.9	1
315	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
316	Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFÎ± cytotoxicity. , 0, .		1
317	Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. Journal of Clinical Oncology, 2013, 31, 307-307.	1.6	1
318	Aids Case for Diagnosis, 1986 Military Medicine. Military Medicine, 1986, 151, M49-M56.	0.8	0
319	Identification of the genes for kidney cancer. Cancer Biology and Therapy, 2006, 5, 696-699.	3.4	0
320	Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. Urology Case Reports, 2020, 30, 101135.	0.3	0
321	Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. Urology Case Reports, 2021, 37, 101603.	0.3	0
322	Protein expression profiling in the spectrum of renal tumors. FASEB Journal, 2007, 21, A181.	0.5	0
323	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	1.6	0